Effects of Switching from Anti-VEGF Treatment to Triamcinolone Acetonide in Eyes with Refractory Macular Edema Associated with Diabetic Retinopathy or Retinal Vein Occlusion

<div>Changes of the intervals for recurrences during anti-VEGF treatments and after switching to TA treatment in eyes with DME (a) and RVO-ME (b). DME: diabetic macular edema; RVO-ME: retinal vein occlusion macular edema; TA: triamcinolone acetonide; VEGF: vascular endothelial growth factor.</div>

BioMed Research International

fig3

Figure 3

Figure 3: Effects of Switching from Anti-VEGF Treatment to Triamcinolone Acetonide in Eyes with Refractory Macular Edema Associated with Diabetic Retinopathy or Retinal Vein Occlusion 

Figure 3 | Effects of Switching from Anti-VEGF Treatment to Triamcinolone Acetonide in Eyes with Refractory Macular Edema Associated with Diabetic Retinopathy or Retinal Vein Occlusion 